高剂量缬沙坦治疗慢性肾小球肾炎合并高血压的疗效观察被引量：6

下载PDF

导出

摘要目的探讨不同剂量缬沙坦治疗慢性肾小球肾炎合并高血压的疗效。方法将76例慢性肾小球肾炎合并高血压患者随机分为A组(38例)和B组(38例),分别给予口服缬沙坦160 mg/d、320 mg/d,疗程为6个月。结果 A组、B组总有效率和不良反应发生率差异均无统计学意义(P>0.05);治疗后,两组患者24 h尿蛋白均较治疗前有显著降低,但B组降低幅度显著大于A组(P<0.05);B组血清肌酐较治疗前有显著降低,肾小球滤过率显著升高(均P<0.05)。结论慢性肾小球肾炎合并高血压患者给予320 mg/d缬沙坦治疗效果更好,可更有效减低尿蛋白和保护肾脏功能,且不增加不良反应。

作者王文胜

机构地区浙江省台州市黄岩区红十字医院内科

出处《健康研究》 CAS 2015年第3期305-306,308,共3页 Health Research

关键词慢性肾小球肾炎高血压缬沙坦剂量

分类号 R544.14 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献7

1马聪,卢学春,范利.血管紧张素Ⅱ受体拮抗剂的临床应用进展[J].中华老年心脑血管病杂志,2011,13(8):762-764. 被引量：7
2远航,刘念,贾冶,许钟镐,苗里宁.不同剂量的缬沙坦延缓糖尿病肾病进展的疗效观察[J].中国老年学杂志,2010,30(1):11-13. 被引量：66
3刘国仗,胡大一,陶萍,诸骏仁,郭林妮,郭静萱,游凯.心血管药物临床试验评价方法的建议[J].中华心血管病杂志,1998,26(1):5-11. 被引量：1440
4王玉,李晓玫.慢性肾脏病与高血压相关研究的热点问题[J].中国实用内科杂志,2007,27(10):814-818. 被引量：16
5贾俊亚,丁国华.肾脏中肾素-血管紧张素系统的生理和病理生理作用[J].生理科学进展,2008,39(1):71-74. 被引量：18
6王远英,孙承美.ARB的肾保护作用机制和临床应用研究进展[J].中国医药导报,2007,4(12S):27-28. 被引量：15
7Lummel N, Lutz J, Briickmann H, et al. The value of magnetic reso- nance imaging for the detection of the bleeding source in non- traumatic intracerebral haemorrhages:a comparison with conventional digital sub- traction angiography[J]. Neuroradiotogy ,2011,42 (9) :219 - 220.

二级参考文献26

1Acourciere Y, Beanger A. Long-term comparison of valsartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy ( J ). Kidney Int,2000 ;58 (2) :762.
2Dahlof B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359,995-1003.
3Verdecchia P, Angeli F,Gattobigio R, et al. Do angiotensin Ⅱ receptor blockers increase the risk of myocardial infarction? Eur Heart J,2005,26:2381-2386.
4Esteban V, Ruperez M, Sdnchez-L6pez E, et al. Angiotensin Ⅳ activates the nuclear transcription faetor--kappaB and relat ed proinflamrnatory genes in vascular smooth muscle cells. Circ Res, 2005,96 : 965-973.
5Takai S,Jin D, Ikeda H,et al. Significance of angiotensin Ⅱ receptor blockers with high affinity to angiotensin Ⅱ type 1 receptors for vascular protection in rats. Hypertens P, es, 2009,32:853-860.
6Navar LG, Nishiyama A. Why are angiotensin concentrations so high in the kidney? Curr Opin Nephrol Hypertens, 2004, 13 : 107 - 115.
7Crowley SD, Gurley SB, Oliverio MI, et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest, 2005, 115 : 1092 - 1099.
8Lasaitiene D, Chen Y, Adams MA, et al. Further insights into the role of angiotensin II in kidney development. Clin Physiol Funct Imaging, 2006, 26 : 197 -204.
9Nguyen G. The (pro) renin receptor: Pathophysiological roles in cardiovascular and renal pathology. Curr Opin Nephrol Hypertens, 2007, 16 : 129- 133.
10Chen J, Chen JK, Neilson EG, et al. Role of EGF receptor activation in angiotensin II-induced renal epithelial cell hypertrophy. J Am Soc Nephrol, 2006, 17 : 1615 - 1623.